A Phase II Randomized Open label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 plus Entinostat in Untreated Advanced Renal Cell Carcinoma (GU17-289)
The purpose of this study is to compare any good and bad effects of using a high dose Interleukin (IL-2) and Entinostat to using IL-2 alone. The addition of Entinostat to high dose IL-2 could shrink your cancer/prevent it from returning for a longer period of time but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
The purpose of this study is to estimate and compare progression free survival (PFS) in patients receiving high dose interleukin 2 or high dose interleukin 2 plus entinostat.
Participants will not be paid for their participation.
- IRB Number: 1712301349
- Research Study Identifier: TX8766
- Principal Investigator: Roberto Pili, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required